Pneumococcal meningitis in adults in 2014-2018 after introduction of pediatric 13-valent pneumococcal conjugate vaccine in Japan.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 02 2022
Historique:
received: 09 09 2021
accepted: 09 02 2022
entrez: 24 2 2022
pubmed: 25 2 2022
medline: 19 3 2022
Statut: epublish

Résumé

We assessed the impact of the pediatric 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis in adults in Japan in 2014-2018 by comparing epidemiological characteristics of adults with invasive pneumococcal disease with (n = 222) and without (n = 1258) meningitis. The annual incidence of pneumococcal meningitis in 2016-2018 was 0.20-0.26 cases/100,000 population. Age (p < 0.001) and case fatality rate (p = 0.003) were significantly lower in patients with meningitis than in those without meningitis. The odds of developing meningitis were higher in asplenic/hyposplenic or splenectomized patients (adjusted odds ratio [aOR] 2.29, 95% CI 1.27-4.14), for serotypes 10A (aOR 3.26, 95% CI 2.10-5.06) or 23A (aOR 3.91, 95% CI 2.47-6.19), but lower for those aged ≥ 65 years (aOR 0.59, 95% CI 0.44-0.81). PCV13 had an indirect effect on nonmeningitis, but its impact on meningitis was limited because of an increase in non-PCV13 serotypes. Of meningitis isolates, 78 (35.1%) and 3 (1.4%) were penicillin G- or ceftriaxone-resistant, respectively. We also confirmed an association of the pbp1bA641C mutation with meningitis (aOR 2.92, 95% CI 1.51-5.65).

Identifiants

pubmed: 35197497
doi: 10.1038/s41598-022-06950-w
pii: 10.1038/s41598-022-06950-w
pmc: PMC8866494
doi:

Substances chimiques

13-valent pneumococcal vaccine 0
Pneumococcal Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3066

Investigateurs

Bin Chang (B)
Kosuke Tamura (K)
Hiroyuki Fujikura (H)
Hiroshi Watanabe (H)
Yoshinari Tanabe (Y)
Koji Kuronuma (K)
Jiro Fujita (J)
Kengo Oshima (K)
Takaya Maruyama (T)
Shuichi Abe (S)
Kei Kasahara (K)
Junichiro Nishi (J)
Tetsuya Kubota (T)
Yuki Kinjo (Y)
Yusuke Serizawa (Y)
Reiko Shimbashi (R)
Munehisa Fukusumi (M)
Tomoe Shimada (T)
Tomimasa Sunagawa (T)
Motoi Suzuki (M)
Kazunori Oishi (K)
Kenji Gotoh (K)
Chikako Tsubata (C)
Hiroki Takahashi (H)
Tetsuji Aoyagi (T)
Masashi Nakamatsu (M)
Naoko Imuta (N)
Akihito Yokoyama (A)
Hiroaki Takeda (H)
Masayuki Ishida (M)

Informations de copyright

© 2022. The Author(s).

Références

Clin Infect Dis. 2021 Oct 5;73(7):e1489-e1497
pubmed: 32716500
Vaccine. 2019 Sep 30;37(42):6201-6207
pubmed: 31495592
MMW Fortschr Med. 2007 May 21;149 Suppl 2:15-8
pubmed: 17724961
Hematology. 2007 Feb;12(1):1-13
pubmed: 17364987
Int J Infect Dis. 2016 Oct;51:27-30
pubmed: 27590561
Nat Rev Microbiol. 2018 Jun;16(6):355-367
pubmed: 29599457
Microorganisms. 2021 Apr 01;9(4):
pubmed: 33916227
J Clin Microbiol. 2015 Oct;53(10):3318-24
pubmed: 26269621
BMC Infect Dis. 2017 Jan 3;17(1):2
pubmed: 28049447
Mol Microbiol. 1999 Aug;33(4):673-8
pubmed: 10447877
J Exp Med. 2003 Apr 7;197(7):939-45
pubmed: 12682112
Clin Microbiol Infect. 2017 Sep;23(9):601-606
pubmed: 28478238
J Clin Microbiol. 1996 Mar;34(3):592-6
pubmed: 8904421
Vaccine. 2015 Nov 9;33(45):6054-60
pubmed: 26235372
J Infect Dis. 1980 Dec;142(6):923-33
pubmed: 7462701
Microorganisms. 2021 Apr 22;9(5):
pubmed: 33922381
Lancet Infect Dis. 2004 Mar;4(3):144-54
pubmed: 14998500
Emerg Infect Dis. 2019 Sep;25(9):1708-1718
pubmed: 31441745
Vaccine. 2020 May 6;38(21):3752-3758
pubmed: 32265047
Emerg Infect Dis. 2018 Jul;24(7):1275-1284
pubmed: 29912694
Hum Vaccin Immunother. 2021 Jul 3;17(7):2249-2256
pubmed: 33545022
J Clin Microbiol. 2010 May;48(5):1611-8
pubmed: 20220175
mBio. 2012 Apr 24;3(3):
pubmed: 22532557
Int J Infect Dis. 2021 Jan;102:260-268
pubmed: 33065297
Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S49-56
pubmed: 19191619
Vaccine. 2021 May 27;39(23):3197-3206
pubmed: 33965258
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Lancet Glob Health. 2018 Jul;6(7):e744-e757
pubmed: 29903376
N Engl J Med. 2011 May 26;364(21):2016-25
pubmed: 21612470
Nat Commun. 2019 Jan 14;10(1):178
pubmed: 30643125

Auteurs

Bin Chang (B)

Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.

Kosuke Tamura (K)

Toyama Institute of Health, 17-1 Nakataiouyama, Imizu, Toyama, 939-0363, Japan.

Hiroyuki Fujikura (H)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Center for Infectious Diseases, Nara Medical University, Nara, Japan.

Hiroshi Watanabe (H)

Department of Infection Control and Prevention, Kurume University School of Medicine, Kurume, Japan.

Yoshinari Tanabe (Y)

Department of Respiratory Medicine, Niigata Prefectural Shibata Hospital, Niigata, Japan.

Koji Kuronuma (K)

Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Hokkaido, Japan.

Jiro Fujita (J)

Department of Infectious Diseases, Respiratory and Digestive Medicine, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.

Kengo Oshima (K)

Department of Infectious Diseases, Tohoku University Hospital, Sendai, Miyagi, Japan.

Takaya Maruyama (T)

Mie Prefectural Ichishi Hospital, Tsu, Mie, Japan.

Shuichi Abe (S)

Yamagata Prefectural Central Hospital, Yamagata, Japan.

Kei Kasahara (K)

Center for Infectious Diseases, Nara Medical University, Nara, Japan.

Junichiro Nishi (J)

Department of Microbiology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Tetsuya Kubota (T)

Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kochi, Japan.

Yuki Kinjo (Y)

Department of Bacteriology, The Jikei University School of Medicine, Tokyo, Japan.

Yusuke Serizawa (Y)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

Reiko Shimbashi (R)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

Munehisa Fukusumi (M)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

Tomoe Shimada (T)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

Tomimasa Sunagawa (T)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

Motoi Suzuki (M)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.

Kazunori Oishi (K)

Toyama Institute of Health, 17-1 Nakataiouyama, Imizu, Toyama, 939-0363, Japan. toyamaeiken1@chic.ocn.ne.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH